(Q44598284)

English

High p27Kip1 Expression Predicts Superior Relapse-Free and Overall Survival for Premenopausal Women With Early-Stage Breast Cancer Receiving Adjuvant Treatment With Tamoxifen Plus Goserelin

scientific article published on October 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

High p27Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

High p27Kip1 Expression Predicts Superior Relapse-Free and Overall Survival for Premenopausal Women With Early-Stage Breast Cancer Receiving Adjuvant Treatment With Tamoxifen Plus Goserelin (English)

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

1 reference

based on heuristic

inferred from title

neoplastic gene expression regulation

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14512390

14 March 2024

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Martin Filipits

12

object named as

Martin Filipits

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14512390

14 March 2024

author name string

Gudrun Pohl

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Margaretha Rudas

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Otto Dietze

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Sigurd Lax

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Eva Markis

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Robert Pirker

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Hubert Hausmaninger

8

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Ernst Kubista

9

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Hellmut Samonigg

10

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Raimund Jakesz

11

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Christoph C. Zielinski

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14512390

14 March 2024

language of work or name

0 references

publication date

1 October 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

full work available at URL

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2003.02.021

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

3594-3600

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Cancer cell cycles

1

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Inhibitors of mammalian G1 cyclin-dependent kinases

2

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Principles of CDK regulation

3

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

p21 is a universal inhibitor of cyclin kinases

4

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals

5

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene

6

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

New functional activities for the p21 family of CDK inhibitors

7

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts

8

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

CDK inhibitors: positive and negative regulators of G1-phase progression

9

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade

11

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents

12

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients

13

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer

14

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Prognostic role of p27Kip1 and apoptosis in human breast cancer

16

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Prognostic impact of cyclin-dependent kinase inhibitor p27kip1 in node-positive breast cancer

17

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

p27 expression correlates with short-term, but not with long-term prognosis in breast cancer

18

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

p27kip1 expression in breast carcinomas: An immunohistochemical study on 512 patients with long-term follow-up

19

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study.

20

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells

21

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian

22

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Nonparametric Estimation from Incomplete Observations

23

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Regression Models and Life-Tables (with discussion)

24

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology

25

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas

27

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27

29

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas.

30

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Ovarian ablation as adjuvant therapy for breast cancer

31

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer

32

1 reference

10.1200/JCO.2003.02.021

https://api.crossref.org/works/10.1200/JCO.2003.02.021

14 March 2024

Identifiers

10.1200/JCO.2003.02.021

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

release_ckqctlrwavcjvekb2fki2k2trm

1 reference

https://api.fatcat.wiki/v0/release/ckqctlrwavcjvekb2fki2k2trm

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44598284&oldid=2102178043"